BioSpecifics Technologies announced that the FDA has accepted for filing and granted priority review of the Biologics License Application (BLA) submitted for Xiaflex. Xiaflex treats Dupuytren’s disease, a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers.

Xiaflex is a first in class collagenase-based product being co-developed by BioSpecifics and Auxilium Pharmaceuticals.

For more information call (516) 593-7000 or visit www.biospecifics.com.